Clinical Research Directory
Browse clinical research sites, groups, and studies.
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Sponsor: Immune Oncology Research Institute
Summary
Chemotherapy-induced nausea and vomiting are serious side effects of cancer treatment that can have a significant negative impact on a patient's quality of life. Although the prevalence of nausea and vomiting has significantly decreased due to the implementation of new antiemetic drugs, several studies revealed that approximately 30% to 60% of patients still complain of acute or delayed chemotherapy-induced emesis. It is estimated that slow infusion of ondansetron in combination with dexamethasone can provide long-lasting stable concentrations of drugs in the blood serum contributing to better effect development. Therefore, the investigators suggest a continuous infusion of the above-mentioned drug combination as an alternative with potential superior activity.
Official title: Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone. Can This Modality Improve the Antiemetic Effect
Key Details
Gender
All
Age Range
Any - 18 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2023-06-27
Completion Date
2025-01-30
Last Updated
2026-06-08
Healthy Volunteers
No
Conditions
Interventions
Ondansetron
Patients will receive age-adjusted doses of ondansetron 5mg/m2
Dexamethasone
Patients will receive dexamethasone 4mg/m2
Locations (1)
Hematology Center named after prof. R. Yeolyan
Yerevan, Armenia